Azelastine/fluticasone propionate - Synmosa Biopharma
Alternative Names: AFC; Azelastine hydrochloride/fluticasone propionate - Synmosa BiopharmaLatest Information Update: 06 Nov 2023
At a glance
- Originator Synmosa Biopharma
- Class Antiallergics; Glucocorticoids; Phthalazines; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Perennial allergic rhinitis
Most Recent Events
- 20 Jul 2021 Synmosa Biopharma completes a phase II trials in Perennial allergic rhinitis (In adults, In the elderly) in Taiwan (Intranasal) (NCT06051786)
- 20 Aug 2020 Phase-II clinical trials in Perennial allergic rhinitis (In adults, In the elderly) in Taiwan (Intranasal) (NCT06051786)